SMC Radiation Oncology SABR Cohort for Oligometastasis

The goal of this observational study is to evaluate the efficacy and safety of stereotactic body radiotherapy (SABR) in patients with oligometastatic or oligoprogressive cancer. The main questions it aims to answer are: 1. oncologic outcomes (progression-free survival, local failure rate), 2. patient-reported outcomes, 3. physician-assessed toxicity, and 4. dynamics of circulating tumor DNA (ctDNA) for biomarker analysis.

NCT Number	NCT07121335
Lead Sponsor	Samsung Medical Center
Conditions	Stereotactic Body Radiation Therapy (SBRT), Oligometastasis, Oligoprogression, ctDNA, Patient-Reported Outcomes (PRO)
Enrollment	60 participants
Start Date	2025-05-01
Primary Completion	2027-12-31 (estimated)
Study Completion	2030-03-31 (estimated)
Updated on ClinicalTrials.gov	2025-08-13